FDA Approves Bristol Myers Squibb's Liver Cancer Drug Combo
Bristol Myers Squibb (NYSE: BMY) announced on Wednesday that its liver cancer drug combo had officially received approval from the U.S. Food and Drug Administration. The Opdivo (nivolumab) plus Yervoy (ipilimumab) treatment will be used in patients with hepatocellular carcinoma (HCC), one of the most aggressive and common types of liver cancer.
The FDA gave the thumbs up to the drug combo based on the results of a phase 1/2 open-label clinical study called Checkmate-040. In this trial, patients who had HCC but were resistant to other treatments -- mainly Nexavar, which is produced by Bayer -- were tested with Opdiov-Yervoy to see if there would be any improvements.
Image source: Getty Images.
Source Fool.com
